|
1
|
Sjödahl G, Lauss M, Lövgren K, Chebil G, Gudjonsson S, Veerla S, Patschan O, Aine M, Fernö M, Ringnér M, et al: A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 18:3377–3386. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A and Bray F: Bladder cancer incidence and mortality: A global overview and recent trends. Eur Urol. 71:96–108. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, Wu R, Chen C, Li X, Zhou L, et al: Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet. 43:875–878. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen M, Zhuang C, Liu Y, Li J, Dai F, Xia M, Zhan Y, Lin J, Chen Z, He A, et al: Tetracycline-inducible shRNA targeting antisense long non-coding RNA HIF1A-AS2 represses the malignant phenotypes of bladder cancer. Cancer Lett. 376:155–164. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Koufopoulou M, Miranda PA, Kazmierska P, Deshpande S and Gaitonde P: Clinical evidence for the first line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options. Cancer Treat Rev. 89:1020722020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee J-L, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, et al KEYNOTE-045 Investigators, : Pembrolizumab as second line therapy for advanced urothelial carcinoma. N Engl J Med. 376:1015–1026. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group, : Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Woll PJ, Judson I, Lee SM, Rodenhuis S, Nielsen OS, Buesa JM, Lorigan PC, Leyvraz S, Hermans C, van Glabbeke M, et al: Temozolomide in adult patients with advanced soft tissue sarcoma: A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 35:410–412. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group, : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang HW, Xu ZK, Song Y and Liu YG: Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: A population-based study in China. Cancer Gene Ther. 24:215–220. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF and Kaina B: Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene. 26:186–197. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mhaidat NM, Zhang XD, Allen J, Avery-Kiejda KA, Scott RJ and Hersey P: Temozolomide induces senescence but not apoptosis in human melanoma cells. Br J Cancer. 97:1225–1233. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, Han W, Lou F, Yang J, Zhang Q, et al: Autophagy and chemotherapy resistance: A promising therapeutic target for cancer treatment. Cell Death Dis. 4:e8382013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Acosta JC and Gil J: Senescence: A new weapon for cancer therapy. Trends Cell Biol. 22:211–219. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM and Lowe SW: A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell. 109:335–346. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R and Jacks T: Restoration of p53 function leads to tumour regression in vivo. Nature. 445:661–665. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang X, Qu K, Tao J, Yin G, Han S, Liu Q and Sun H: Inhibition of CIP2A attenuates tumor progression by inducing cell cycle arrest and promoting cellular senescence in hepatocellular carcinoma. Biochem Biophys Res Commun. 495:1807–1814. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Codogno P and Meijer AJ: Autophagy and signaling: Their role in cell survival and cell death. Cell Death Differ. 12 (Suppl 2):1509–1518. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rosenfeldt MT and Ryan KM: The role of autophagy in tumour development and cancer therapy. Expert Rev Mol Med. 11:e362009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Manic G, Obrist F, Kroemer G, Vitale I and Galluzzi L: Chloroquine and hydroxychloroquine for cancer therapy. Mol Cell Oncol. 1:e299112014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang M, Liao C, Hu Y, Qinwen Pan and Jiang J: Sensitization of breast cancer cells to paclitaxel by dichloroacetate through inhibiting autophagy. Biochem Biophys Res Commun. 489:103–108. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mahoney JR and Eaton JW: Chloroquine resistant malaria: Association with enhanced plasmodial protease activity. Biochem Biophys Res Commun. 100:1266–1271. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kimura T, Takabatake Y, Takahashi A and Isaka Y: Chloroquine in cancer therapy: A double-edged sword of autophagy. Cancer Res. 73:3–7. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Verschooten L, Barrette K, Van Kelst S, Rubio Romero N, Proby C, De Vos R, Agostinis P and Garmyn M: Autophagy inhibitor chloroquine enhanced the cell death inducing effect of the flavonoid luteolin in metastatic squamous cell carcinoma cells. PLoS One. 7:e482642012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Amaravadi RK, Yu D, Lum JJ, Thomas Tikhonenko A and Thompson CB: Inhibition of autophagy with chloroquine enhances therapeutic tumor regression in a mouse model of B cell lymphoma. Cancer Res. 66:14482006.
|
|
26
|
Liu T, Zhang J, Li K, Deng L and Wang H: Combination of an autophagy inducer and an autophagy inhibitor: A smarter strategy emerging in cancer therapy. Front Pharmacol. 11:4082020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim NY, Kim MC and Kim Y: Hypomethylation reduced the aggressive potential of human malignant mesothelioma cells. Cancer Gene Ther. 23:425–432. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim HA, Kim MC, Kim NY and Kim Y: Inhibition of hedgehog signaling reduces the side population in human malignant mesothelioma cell lines. Cancer Gene Ther. 22:387–395. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sun Z, Niu S, Xu F, Zhao W, Ma R and Chen M: CircAMOTL1 promotes tumorigenesis through miR 526b/SIK2 axis in cervical cancer. Front Cell Dev Biol. 8:5681902020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Leikam C, Hufnagel A, Schartl M and Meierjohann S: Oncogene activation in melanocytes links reactive oxygen to multinucleated phenotype and senescence. Oncogene. 27:7070–7082. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ning ZF, Huang YJ, Lin TX, Zhou YX, Jiang C, Xu KW, Huang H, Yin XB and Huang J: Subpopulations of stem-like cells in side population cells from the human bladder transitional cell cancer cell line T24. J Int Med Res. 37:621–630. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen M, Wei X, Shi X, Lu L, Zhang G, Huang Y and Hou J: LncRNA HIF1A-AS2 accelerates malignant phenotypes of renal carcinoma by modulating miR-30a-5p/SOX4 axis as a ceRNA. Cancer Biol Med. 18:587–603. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kai K, D'Costa S, Yoon BI, Brody AR, Sills RC and Kim Y: Characterization of side population cells in human malignant mesothelioma cell lines. Lung Cancer. 70:146–151. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ewald JA, Desotelle JA, Wilding G and Jarrard DF: Therapy-induced senescence in cancer. J Natl Cancer Inst. 102:1536–1546. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yi G, He Z, Zhou X, Xian L, Yuan T, Jia X, Hong J, He L and Liu J: Low concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathway. Int J Oncol. 43:1503–1510. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Olivier M, Petitjean A, Marcel V, Pétré A, Mounawar M, Plymoth A, de Fromentel CC and Hainaut P: Recent advances in p53 research: An interdisciplinary perspective. Cancer Gene Ther. 16:1–12. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chang BD, Xuan Y, Broude EV, Zhu H, Schott B, Fang J and Roninson IB: Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene. 18:4808–4818. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang D, Song J, Wu L, Ma Y, Song C, Dovat S, Nishizaki T and Liu J: Induction of senescence by adenosine suppressing the growth of lung cancer cells. Biochem Biophys Res Commun. 440:62–67. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li P, Zhao M, Parris AB, Feng X and Yang X: p53 is required for metformin-induced growth inhibition, senescence and apoptosis in breast cancer cells. Biochem Biophys Res Commun. 464:1267–1274. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gewirtz DA, Holt SE and Elmore LW: Accelerated senescence: An emerging role in tumor cell response to chemotherapy and radiation. Biochem Pharmacol. 76:947–957. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Moserle L, Ghisi M, Amadori A and Indraccolo S: Side population and cancer stem cells: Therapeutic implications. Cancer Lett. 288:1–9. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tanida I, Ueno T and Kominami E: LC3 and autophagy. Methods Mol Biol. 445:77–88. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rotondo R, Oliva MA, Staffieri S, Castaldo S, Giangaspero F and Arcella A: Implication of lactucopicrin in autophagy, cell cycle arrest and oxidative stress to inhibit U87Mg glioblastoma cell growth. Molecules. 25:58432020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Moghadam AR, da Silva Rosa SC, Samiei E, Alizadeh J, Field J, Kawalec P, Thliveris J, Akbari M, Ghavami S and Gordon JW: Autophagy modulates temozolomide-induced cell death in alveolar Rhabdomyosarcoma cells. Cell Death Discov. 4:522018.Erratum in: Cell Death Discov 5: 116, 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ganguli A, Choudhury D, Datta S, Bhattacharya S and Chakrabarti G: Inhibition of autophagy by chloroquine potentiates synergistically anti-cancer property of artemisinin by promoting ROS dependent apoptosis. Biochimie. 107((Pt B)): 338–349. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liang X, Tang J, Liang Y, Jin R and Cai X: Suppression of autophagy by chloroquine sensitizes 5-fluorouracil-mediated cell death in gallbladder carcinoma cells. Cell Biosci. 4:102014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yoon YH, Cho KS, Hwang JJ, Lee SJ, Choi JA and Koh JY: Induction of lysosomal dilatation, arrested autophagy, and cell death by chloroquine in cultured ARPE-19 cells. Invest Ophthalmol Vis Sci. 51:6030–6037. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Rao R, Balusu R, Fiskus W, Mudunuru U, Venkannagari S, Chauhan L, Smith JE, Hembruff SL, Ha K, Atadja P, et al: Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells. Mol Cancer Ther. 11:973–983. 2012. View Article : Google Scholar : PubMed/NCBI
|
